Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$38.71M, compared with -$44.11M a year earlier. Trailing-twelve-month EBITDA was -$153.62M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $2.5M (+101.6%) for the fiscal year ending Dec 2026, a step up from the -27.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$38.71M-4.6% QoQ
- Last fiscal yearDec 2025
- -$159.02M-27.0% YoY
- LTMMar 2026
- -$153.62M-5.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.2% | +100.0% | +87.8 pp |
| 1 year | -27.0% | +101.6% | +128.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (159.02M) USD
- Year-over-year change
- -27.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (159.02M) | -27.0% |
| FY2024 | 2024-12-31 | (125.2M) | -114.1% |
| FY2023 | 2023-12-31 | (58.47M) | -110.5% |
| FY2022 | 2022-12-31 | (27.78M) | -7.8% |
| FY2021 | 2021-12-31 | (25.76M) | — |
EBITDA vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 EBITDA of -$153.62M is the 7th highest of the 11 companies compared; the peer median is -$92.64M.
- Its year-over-year change of -5.2% is the 6th highest of 10, against a peer median of +13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
| LTM Mar 2026 | -$39.29M | +13.4% | — | 7858.4% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.12M | -17.3% | — | — |
| LTM Mar 2026 | -$78.13M | — | — | 8478.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M | +20.5% | — | — |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$153.62M | -5.2% | — | — | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$171.58M | -48.1% | — | — | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| LTM Mar 2026 | -$238.99M | -27.7% | — | 770932.3% | |
| Peer median (excluding KYTX) | -$92.64M | +13.4% | — | 8168.4% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| Weighted Avg Shares | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
| Weighted Avg Shares (Diluted) | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.